Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. Howe...

Descripción completa

Detalles Bibliográficos
Autores: Arriola, Edurne, Castro, Javier de, García Campelo, María Rosario, Bernárdez, Beatriz, Bernabé, Reyes, Bruna, Jordi, Domine Gómez, Manuel, Isla, Dolores, Juan‑Vidal, Óscar, López‑Fernández, Teresa, Nadal, Ernest, Rodríguez Abreu, Delvys, Vares, María, Asensio, Úrsula, García, Luis F., Felip, Enriqueta
Tipo de recurso: informe técnico
Fecha de publicación:2024
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:dnet:biblosearchi::673ea847ed140f0f9558dca1dad3ca01
Acceso en línea:https://hdl.handle.net/10486/758800
https://dx.doi.org/10.1007/s40261-024-01379-7
Access Level:acceso abierto
Palabra clave:Aminopyridines
Anaplastic Lymphoma Kinase
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Lactams, Macrocyclic
Protein Kinase Inhibitors
Pyrazoles
Medicina
Descripción
Sumario:The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts

Similares en LA Referencia